


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6627763/publications.pdf Version: 2024-02-01



he Ni

#	Article	IF	CITATIONS
1	Acquisition of epithelial–mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death and Disease, 2013, 4, e875-e875.	6.3	321
2	PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death and Disease, 2014, 5, e1437-e1437.	6.3	256
3	Cancer stem cell in breast cancer therapeutic resistance. Cancer Treatment Reviews, 2018, 69, 152-163.	7.7	197
4	Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. International Journal of Biochemistry and Cell Biology, 2013, 45, 2736-2748.	2.8	155
5	Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Critical Reviews in Oncology/Hematology, 2015, 96, 507-517.	4.4	154
6	Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer, 2019, 19, 618.	2.6	153
7	CD44 variant 6 is associated with prostate cancer metastasis and chemoâ€∤radioresistance. Prostate, 2014, 74, 602-617.	2.3	126
8	Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis. Theranostics, 2020, 10, 2309-2326.	10.0	124
9	Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?. Cancer Letters, 2021, 497, 100-111.	7.2	107
10	Exosomes and breast cancer drug resistance. Cell Death and Disease, 2020, 11, 987.	6.3	103
11	Cancer stem cells and signaling pathways in radioresistance. Oncotarget, 2016, 7, 11002-11017.	1.8	92
12	Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget, 2016, 7, 55771-55788.	1.8	85
13	Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer. Critical Reviews in Oncology/Hematology, 2020, 145, 102860.	4.4	73
14	The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer and Metastasis Reviews, 2013, 32, 535-551.	5.9	71
15	Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer and Metastasis Reviews, 2012, 31, 779-791.	5.9	68
16	Urinary biomarkers in prostate cancer detection and monitoring progression. Critical Reviews in Oncology/Hematology, 2017, 118, 15-26.	4.4	64
17	Targeting MicroRNAs in Prostate Cancer Radiotherapy. Theranostics, 2017, 7, 3243-3259.	10.0	64
18	Exosomes in Cancer Radioresistance. Frontiers in Oncology, 2019, 9, 869.	2.8	60

Jie Ni

#	Article	IF	CITATIONS
19	Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach. Scientific Reports, 2017, 7, 41834.	3.3	59
20	Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression. Theranostics, 2019, 9, 4130-4140.	10.0	59
21	Cancer stem cells in prostate cancer radioresistance. Cancer Letters, 2019, 465, 94-104.	7.2	49
22	Cancer Stem Cells in Prostate Cancer Chemoresistance. Current Cancer Drug Targets, 2014, 14, 225-240.	1.6	48
23	Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells. PLoS ONE, 2013, 8, e74253.	2.5	35
24	Activation of the eIF2α/ATF4 axis drives triple-negative breast cancer radioresistance by promoting glutathione biosynthesis. Redox Biology, 2021, 43, 101993.	9.0	30
25	Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. Cancer Letters, 2013, 329, 17-26.	7.2	29
26	Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo. BMC Cancer, 2018, 18, 1092.	2.6	29
27	Endoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link. Frontiers in Cell and Developmental Biology, 2021, 9, 683940.	3.7	26
28	Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy. Oncotarget, 2016, 7, 74269-74285.	1.8	24
29	A Clinician's Guide to Cancer-Derived Exosomes: Immune Interactions and Therapeutic Implications. Frontiers in Immunology, 2020, 11, 1612.	4.8	21
30	Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance. Journal of the National Cancer Center, 2021, 1, 75-87.	7.4	20
31	Monitoring Prostate Tumor Growth in an Orthotopic Mouse Model Using Three-Dimensional Ultrasound Imaging Technique. Translational Oncology, 2016, 9, 41-45.	3.7	18
32	THOC2 and THOC5 Regulate Stemness and Radioresistance in Tripleâ€Negative Breast Cancer. Advanced Science, 2021, 8, e2102658.	11.2	17
33	<p>Quality Assessment and Comparison of Plasma-Derived Extracellular Vesicles Separated by Three Commercial Kits for Prostate Cancer Diagnosis</p> . International Journal of Nanomedicine, 2020, Volume 15, 10241-10256.	6.7	16
34	Clinical Evaluation and Patient Satisfaction of Single Zirconiaâ€Based and Highâ€Noble Alloy Porcelainâ€Fusedâ€ŧoâ€Metal Crowns in the Esthetic Area: A Retrospective Cohort Study. Journal of Prosthodontics, 2016, 25, 526-530.	3.7	14
35	Enhanced osteointegration of tantalum-modified titanium implants with micro/nano-topography. RSC Advances, 2017, 7, 46472-46479.	3.6	11
36	CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target. Frontiers in Oncology, 2019, 9, 557.	2.8	11

Jie Ni

#	Article	IF	CITATIONS
37	Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy. Expert Review of Proteomics, 2016, 13, 905-915.	3.0	8
38	In Vivo 3D MRI Measurement of Tumour Volume in an Orthotopic Mouse Model of Prostate Cancer. Cancer Control, 2019, 26, 107327481984659.	1.8	8
39	CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo. Experimental Cell Research, 2020, 388, 111850.	2.6	7
40	The CD44 Isoforms in Prostate Cancer Metastasis and Progression. World Journal of Cancer Research, 2013, 1, 3-14.	0.2	3
41	Abstract 1999: Study of CD44 variant 6 (CD44v6) in prostate cancer chemo-/radio resistance in vivo. , 2018, , .		1
42	Abstract 4754: CHTOP is a novel therapeutic target for chemoresistant epithelial ovarian cancer therapy. , 2019, , .		1
43	Studying CD44 variant 6 (CD44v6) in prostate cancer progression and chemo-/radio-resistance using in vivo mouse models. Annals of Oncology, 2017, 28, x78-x79.	1.2	0
44	Abstract A283: PI3K/Akt/mTOR dual inhibitors have an advantage over single inhibitors in overcoming prostate cancer radioresistance , 2013, , .		0
45	Abstract 4005: CD44 isoform variant 6 is associated with prostate cancer progression, metastasis and chemo-/radio-resistance via PI3K/Akt/mTOR and Wnt/l²-catenin signaling pathwaysin vitro. , 2014, , .		0
46	Abstract 2001: Identification of lactate dehydrogenase A (LDHA) as a potential therapeutic target for prostate cancer radiotherapy. , 2015, , .		0
47	Abstract 2833: Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer progression and chemo-/radio-resistanceinvitroandin vivo. , 2017, , .		0
48	Abstract 4754: CHTOP is a novel therapeutic target for chemoresistant epithelial ovarian cancer therapy. , 2019, , .		0
49	Abstract 6163: Integrated stress response contributes to triple negative breast cancer radioresistance by regulating glutathione biosynthesis. , 2020, , .		О